Chinese Academy of Medical Sciences, Fuwai Hospital
Phase
Observational
Started
2021-01-01
Last updated
2025-08-12
Condition(s) studied
Coronary Artery DiseasePercutaneous Coronary Intervention (PCI)Atherosclerosis of Coronary Artery
Investigational drug(s) / intervention(s)
CCTA-derived Plaque Quantification
CCTA-derived Plaque Quantification: Quantitative analysis of coronary plaque features based on coronary CT angiography using semi-automated software.
Study summary
Despite the widespread use of stents, previous studies have shown that stent implantation mainly relieves symptoms but may not significantly improve long-term outcomes in patients with stable coronary artery disease. Identifying the types of plaques that are most likely to benefit from stenting is essential for improving personalized treatment. This study explores whether coronary computed tomography angiography (CCTA)-derived imaging biomarkers of coronary plaques are associated with increased risk of adverse outcomes after percutaneous coronary intervention (PCI). Around 2,000 patients who underwent CCTA followed by stent placement were included. Advanced software was used to quantify plaque inflammation and composition. Findings from this research may help guide personalized treatment strategies in patients undergoing PCI.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. patients aged 18 years or older;
2. patients who underwent clinically indicated PCI within 30 days following CCTA;
3. CCTA demonstrating the presence of coronary atherosclerotic plaque.
Exclusion Criteria:
1. patients whose PCI within 30 days after CCTA was performed on an emergency basis;
2. elevated cardiac troponin levels within the 3 months preceding PCI;
3. inadequate CCTA image quality;
4. balloon-only or mixed stent/balloon PCI strategies;
5. PCI for non-atherosclerotic lesions (e.g., in-stent restenosis, spontaneous coronary dissection);
6. history of coronary artery bypass grafting;
7. heart failure;
8. non-ischemic cardiomyopathy;
9. significant valvular heart disease;
10. refractory hypertension;
11. persistent atrial fibrillation.
Primary outcome measure(s)
Major adverse cardiovascular events (MACE) — From the date of PCI until December 2024 (minimum 2-year follow-up) Composite of cardiovascular death, non-fatal myocardial infarction, repeat revascularization, and hospitalization for unstable angina.
Trial sites (3)
Facility
City
Region
Status
Fuwai Hospital, Chinese Academy of Medical Sciences
Beijing
Beijing Municipality
Tai'an Central Hospital
Tai’an
Shandong
Weifang People's Hospital
Weifang
Shandong
More Chinese Academy of Medical Sciences, Fuwai Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.